Israeli biotech company Cell Cure Neurosciences, a subsidiary of biotech giant BioTime, has announced that it has received a $1.33 million grant from The Israeli Chief Scientist Office.
The company says that it will use the funds to finance the development of its latest product, OpRegen, a cell-based treatment for macular degeneration, an age-related condition that impairs vision. The company has also announced that it will apply for human trials of the treatment this year.
Related posts
UN Honors Israeli Food Exec For Sustainability Work
September 26, 2023
Startup Unveils Tech To Speed Up Growth Of Cultivated Meat
September 26, 2023
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Facebook comments